Homecare Diagnostics and Therapeutics Market By Product (Diagnostic Products, Therapeutic Products, Mobility Care Products), By Service (Rehabilitation Therapy Services, Skilled Nursing Services, Respiratory Therapy Services, Pregnancy Care Services, Infusion Therapy Services), By Indication (Cardiovascular Disorders, Cancer, Diabetes, Respiratory Diseases, Wound Care), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Homecare Diagnostics and Therapeutics Market was valued at USD 214.1 billion in 2023 and will surpass USD 374.7 billion by 2030; growing at a CAGR of 8.3% during 2024 - 2030.

The Homecare Diagnostics and Therapeutics market is expanding rapidly, driven by the increasing demand for cost-effective, patient-centric healthcare solutions. The rising prevalence of chronic diseases, coupled with advancements in medical technology, has fostered a shift from hospital-based care to home-based alternatives. This transition is reinforced by the aging population, increasing healthcare costs, and growing awareness of the benefits of homecare solutions.

Diagnostic Products Segment Is Largest Owing to Demand for At-Home Testing Solutions

Diagnostic products are the largest segment in the market due to the increasing adoption of at-home testing kits for monitoring various health conditions. These products offer convenience, accessibility, and cost savings for patients managing chronic diseases like diabetes and cardiovascular disorders. Blood glucose monitors, pregnancy test kits, and point-of-care devices are among the most widely used diagnostic products.

The integration of digital technologies, such as smartphone compatibility and AI-powered analytics, has further enhanced the functionality and accuracy of these devices. With the ongoing trend toward preventative care and early diagnosis, the demand for diagnostic products is expected to remain robust, driving innovation and market growth.

Respiratory Therapy Services Are Fastest Growing Owing to Rising Prevalence of Chronic Respiratory Conditions

Respiratory therapy services are the fastest-growing segment under the services category, driven by the increasing prevalence of respiratory diseases such as COPD, asthma, and sleep apnea. Home-based respiratory therapies, including oxygen therapy and CPAP devices, have become essential for managing these conditions.

The integration of telemedicine and remote monitoring technologies has further enhanced the efficacy of respiratory therapy services. These innovations enable real-time tracking of patient progress, ensuring timely adjustments to treatment plans and reducing the burden on healthcare facilities.

Diabetes Indication Is Largest Owing to Self-Monitoring Devices

Diabetes is the largest segment by indication, driven by the increasing prevalence of the disease and the growing emphasis on self-monitoring. Devices such as blood glucose monitors and continuous glucose monitoring systems are indispensable tools for patients managing diabetes at home.

Technological advancements, including connectivity with mobile applications and cloud-based platforms, have further enhanced the usability and accuracy of these devices. This integration allows patients to monitor their glucose levels in real-time and share data with healthcare providers, ensuring effective disease management.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure

North America leads the Homecare Diagnostics and Therapeutics market, driven by its advanced healthcare infrastructure, high adoption rates of homecare solutions, and favorable reimbursement policies. The region’s strong presence of key market players and technological innovation further solidifies its dominance.

The United States, in particular, is a major contributor, benefiting from the growing prevalence of chronic diseases and the increasing preference for home-based care. Investments in telehealth and AI-driven diagnostic tools are also driving market growth in the region.

Competitive Landscape and Leading Companies

The competitive landscape of the Homecare Diagnostics and Therapeutics market is marked by intense competition and continuous innovation. Leading companies such as Medtronic, Abbott Laboratories, Philips Healthcare, Fresenius Medical Care, and Becton, Dickinson and Company are driving market growth through product launches, strategic partnerships, and mergers and acquisitions.

Recent Developments:

• In February 2023, Abbott acquired Tactiq Biosystems for $4.75 billion, enhancing its portfolio in homecare diagnostics
• In April 2023, the FDA approved the first at-home test for Lyme disease, marking a significant advancement in home diagnostics.
• In October 2024, Exact Sciences received FDA approval for its new colon cancer detection test, Cologuard Plus.
• In November 2024, Roche Holding's experimental antibody for Alzheimer's, trontinemab, showed significant promise in clinical trials.

List of Leading Companies:

• Fresenius SE & Co. KGaA
• GE Healthcare
• Linde plc
• F. Hoffmann-La Roche Ltd.
• A&D Company
• BAYADA Home Health Care
• Invacare Corporation
• Abbott Laboratories
• Amedisys
• ResMed
• Johnson & Johnson
• Philips Healthcare
• Omron Healthcare
• Medtronic
• Fitbit

Report Scope: